Evidence map›Paper›PMID 28747201›Full record

ArticleBMC pulmonary medicine2017

Intravenous superoxide dismutase as a protective agent to prevent impairment of lung function induced by high tidal volume ventilation.

Nan-Chun Wu, Fan-Ting Liao, Hao-Min Cheng, Shih-Hsien Sung, Yu-Chun Yang, Jiun-Jr Wang

Open access · goldAbstract read
In one paragraph

Article in BMC pulmonary medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Effect of Sheng-Jiang Powder on Obesity-Induced Multiple Organ Injuries in Rats.Evidence-based complementary and alternative medicine : eCAM · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Nan-Chun WuDivision of Cardiovascular Surgery, Department of Surgery, Chi-Mei Foundation Hospital, 901, Chung Hwa Rd. Yung Kang, Tainan, Taiwan.
Fan-Ting LiaoSchool of Medicine, Fu Jen Catholic University, No. 510, Zhongzheng Rd., Xinzhuang Dist, New Taipei City, 24205, Taiwan.
Hao-Min ChengDepartment of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan.
Shih-Hsien SungDivision of Cardiology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Yu-Chun YangSchool of Medicine, Fu Jen Catholic University, No. 510, Zhongzheng Rd., Xinzhuang Dist, New Taipei City, 24205, Taiwan.
Jiun-Jr WangSchool of Medicine, Fu Jen Catholic University, No. 510, Zhongzheng Rd., Xinzhuang Dist, New Taipei City, 24205, Taiwan. 078625@mail.fju.edu.tw.
Fu Jen Catholic University · TWNational Yang Ming Chiao Tung University · TWChi Mei Medical Center · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPositive-pressure mechanical ventilation is essential in assisting patients with respiratory failure in the intensive care unit and facilitating oxygenation in the operating room. However, it was also recognized as a primary factor leading to hospital-acquired pulmonary dysfunction, in which pulmonary oxidative stress and lung inflammation had been known to play important roles. Cu/Zn superoxide dismutase (SOD) is an important antioxidant, and possesses anti-inflammatory capacity. In this study, we aimed to study the efficacy of Cu/Zn SOD, administered intravenously during high tidal volume (HTV) ventilation, to prevent impairment of lung function.

methodsThirty-eight male Sprague-Dawley rats were divided into 3 groups: 5 h ventilation with (A) low tidal volume (LTV; 8 mL/kg; n = 10), (B) high tidal volume (HTV; 18 mL/kg; n = 14), or (C) HTV and intravenous treatment of Cu/Zn SOD at a dose of 1000 U/kg/h (HTV + SOD; n = 14). Lung function was evaluated both at baseline and after 5-h ventilation. Lung injury was assessed by histological examination, lung water and protein contents in the bronchoalveolar lavage fluid (BALF). Pulmonary oxidative stress was examined by concentrations of methylguanidine (MG) and malondialdehyde (MDA) in BALF, and antioxidative activity by protein expression of glutathione peroxidase-1 (GPx-1) in the lung. Severity of lung inflammation was evaluated by white blood cell and differential count in BALF, and protein expression of inducible nitric oxide synthase (iNOS), intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-α (TNF-α), matrix metalloproteinase-9 (MMP-9), and mRNA expression of nuclear factor-κB (NF-κB) in the lung. We also examined protein expression of surfactant protein (SP)-A and D and we measured hourly changes in serum nitric oxide (NO) level.

resultsFive hours of LTV ventilation did not induce a major change in lung function, whereas 5 h of HTV ventilation induced apparent combined restrictive and obstructive lung disorder, together with increased pulmonary oxidative stress, decreased anti-oxidative activity and increased lung inflammation (P < 0.05). HTV ventilation also decreased SP-A and SP-D expression and suppressed serum NO level during the time course of ventilation. Cu/Zn SOD administered intravenously during HTV ventilation effectively reversed associated pulmonary oxidative stress and lung inflammation (P < 0.05); moreover, it preserved SP-A and SP-D expressions in the lung and increased serum nitric oxide (NO) level, enhancing vascular NO bioavailability.

conclusionsHTV ventilation can induce combined restrictive and obstructive lung disorders. Intravenous administration of Cu/Zn SOD during HTV ventilation can prevent lung function impairment and lung injury via reducing pulmonary oxidative stress and lung inflammation, preserving pulmonary surfactant expression, and enhancing vascular NO bioavailability.

Indexed as

Administration, IntravenousAnimalsBronchoalveolar Lavage FluidFree Radical ScavengersGlutathione PeroxidaseGlutathione Peroxidase GPX1Intercellular Adhesion Molecule-1Leukocyte Common AntigensLungMaleMatrix Metalloproteinase 9NF-kappa BNitric Oxide Synthase Type IIPositive-Pressure RespirationPulmonary Surfactant-Associated Protein APulmonary Surfactant-Associated Protein DFree Radical ScavengersGlutathione PeroxidaseGlutathione Peroxidase GPX1Gpx1 protein, ratIntercellular Adhesion Molecule-1Leukocyte Common AntigensMatrix Metalloproteinase 9Mmp9 protein, ratNF-kappa BNitric Oxide Synthase Type IINos2 protein, ratPulmonary Surfactant-Associated Protein APulmonary Surfactant-Associated Protein DRNA, MessengerSuperoxide DismutaseTumor Necrosis Factor-alphaInflammationLung functionNitric oxideOxidative stressPositive pressure mechanical ventilationRatsSuperoxide dismutaseSurfactant protein ASurfactant protein D

Identifiers

PMID28747201
PMCPMC5530466
OpenAlexW2739148669

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.